Systemic corticosteroids are not effective for symptom control in patients with acute rhinosinusitis.
ATS 2021, News
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Patients with asthma are at higher risk of pulmonary embolism, particularly if the asthma is severe or they take oral corticosteroids.
Highest rates of adverse events seen within first month after initiating short course of oral steroids.
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
AAAAI 2021, News
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.